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Iliofemoral venous thrombosis
Anthony J. Comerota, MD, and Marilyn H. Gravett, MFA, Toledo, Ohio
Iliofemoral deep vein thrombosis (DVT) is associated with serious short- and long-term physical, social, and economic
sequelae for patients. Most physicians treat patients with acute iliofemoral DVT in the same manner as they treat all acute
DVT patients: with anticoagulation alone. Yet a growing body of evidence suggests that, in this subset of DVT patients,
a treatment strategy that includes thrombus removal plus optimal anticoagulation significantly improves outcomes. This
article reviews the evidence supporting this strategy and discusses current and promising techniques of thrombus
removal, including contemporary venous thrombectomy, intrathrombus catheter-directed thrombolysis, and pharmaco-
mechanical thrombolysis. ( J Vasc Surg 2007;46:1065-76.)Iliofemoral deep venous thrombosis (DVT) is associ-
ated with serious short-term and long-term physical, social,
and economic sequelae for patients.1-3 Yet, despite evi-
dence demonstrating that patients with iliofemoral DVT
have more severe post-thrombotic morbidity than patients
with infrainguinal DVT, most physicians treat all DVT
patients alike—with anticoagulation alone. A treatment
approach that includes a strategy of thrombus removal plus
optimal anticoagulation is not considered by most clini-
cians, even in patients with extensive venous thrombosis.
Certainly, advances in anticoagulation have been enor-
mous. The low-molecular-weight heparins (LMWH) and
pentasaccharides, as well as new direct thrombin inhibitors,
limit the progression of thrombosis, reduce recurrence with
a proper duration of therapy, and can properly manage
patients with heparin-induced thrombocytopenia (with or
without thrombosis). However, none of these agents re-
move existing thrombus from the deep venous system.
After anticoagulation alone for management of iliofem-
oral DVT, post-thrombotic chronic venous insufficiency,
leg ulceration, and venous claudication are common.1-3
O’Donnell et al1 were among the first to describe the
increased severity of post-thrombotic symptoms in these
patients: 67% required recurrent (5) hospitalizations and
81% experienced loss of financial productivity. Akesson et al2
demonstrated that 95% of patients treated with anticoagu-
lation alone had ambulatory venous hypertension at 5
years, 90% had signs and symptoms of chronic venous
insufficiency, venous ulcers developed in 15%, and 15%
showed symptoms of venous claudication. According to
Delis et al,3 40% of patients with prior iliofemoral DVT
treated with anticoagulation alone had venous claudication
when exercised.
Recurrent DVT is known to be a high risk factor for
post-thrombotic morbidity.4 Patients with iliofemoral DVT
have been shown to have a 2.6-fold higher risk of recurrence
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Considering the body of evidence to date, patients with
acute iliofemoral DVT should be offered a strategy of throm-
bus removal6,7 as the preferred initial management to improve
long-term outcome by reducing post-thrombotic morbidity.
UNDERSTANDING POST-THROMBOTIC
VENOUS INSUFFICIENCY
Many physicians fail to recognize the difference in the
pathophysiology of primary vs post-thrombotic venous in-
sufficiency. As a consequence, they underestimate the value
of thrombus removal in preventing post-thrombotic mor-
bidity, especially in patients with iliofemoral DVT.
The pathophysiology of chronic venous insufficiency is
ambulatory venous hypertension, which is defined as an
elevated venous pressure during exercise.8 The anatomic
components that contribute to ambulatory venous hyper-
tension are venous valvular incompetence and luminal ob-
struction. Studies consistently show that patients with
chronic venous obstruction have the most severe post-
thrombotic morbidity.8,9 Although this is generally true for
all segments of the venous system, multisegment venous
involvement10,11 and iliofemoral obstruction result in the
most profound morbidity.
Venous obstruction is not synonymous with occlusion.
Obstruction can include mild, moderate, or severe luminal
compromise, or even occlusion; therefore, obstruction is a
relative term whereas occlusion is absolute. Unfortunately,
technology has not advanced to the point that allows
physicians to assess the pathophysiologic impact of partial
luminal obstruction in an individual patient. Fig 1 is an
illustrative example of a patient who had multichannel
(partial) recanalization of his femoral vein lumen after
iliofemoral DVT. Despite most of the vein lumen remain-
ing obstructed, phlebography and physiologic testing failed
to identify obstruction as part of the patient’s pathophysi-
ology. There remains widespread under-appreciation for
the importance of luminal obstruction contributing to
post-thrombotic morbidity and, therefore, widespread un-
der-appreciation of the benefit of thrombus removal when
the patient presents with acute iliofemoral DVT.
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It has become increasingly evident that thrombus re-
moval or early thrombus resolution after the onset of acute
DVT is associated with improved outcomes. Experimental
observations, natural history studies of acute DVT, venous
thrombectomy data, and observations after systemic and
catheter-directed thrombolysis all confirm that a strategy of
thrombus removal reduces post-thrombotic morbidity.
Experimental observations of acute DVT in canine
models demonstrated that thrombolysis preserves endo-
thelial function and valve competence immediately and
at 4 weeks after therapy compared with placebo. There
was less residual thrombus in veins treated with a plas-
minogen activator, thereby preserving the vein’s struc-
tural integrity.12,13
These experimental observations translate into improved
clinical outcomes when spontaneous clot lysis was observed in
a natural history study of acute DVT in patients treated with
anticoagulation.14-16 These investigators found that distal
valvular incompetence developed in patients with persistent
proximal vein obstruction, even when distal veins had no
thrombus involvement.14 They confirmed that the combina-
tion of venous obstruction and valve incompetence was asso-
ciated with the most severe post-thrombotic morbidity.15
Spontaneous clot lysis naturally restored venous patency.
Moreover, if spontaneous lysis occurred early (90 days),
valve function was frequently preserved.16
Persistent thrombus at termination of anticoagulation is
Fig 1. A, Ascending phlebography in a patient with po
evidence of obstruction” and the result of an impedance
procedure revealed considerable luminal obstruction of
namic measurements diagnosed accurately. Adapted fromassociated with recurrent DVT. Two prospective cohort stud-ies of acute DVT treated with conventional anticoagulation
monitored patients with venous ultrasound imaging.17,18
Both found that residual venous thrombus significantly re-
duced the risk of recurrence. Therefore, normalization of vein
segments involved with acute thrombosis would appear
to significantly reduce the risk of recurrence and post-
thrombotic syndrome. Patients with iliofemoral DVT have
a larger thrombus burden at the outset of treatment and,
therefore, will likely have a larger residual thrombus burden
at the completion of anticoagulation. Douketis et al5 doc-
umented the anticipated observation that patients with
iliofemoral DVT treated with anticoagulation alone had a
significantly higher risk of recurrent DVT compared with
patients with infrainguinal DVT. It is well recognized that
recurrent DVT significantly increases the risk of post-
thrombotic morbidity.4
The early trials of thrombolytic therapy for acute DVT
involved systemic infusion of the plasminogen activator.
The cumulative results of these trials revealed that although
45% of patients had substantial or complete lysis, most did
not.19 However, those whose clot was successfully lysed
had a significant reduction in post-thrombotic morbidity
and preservation of venous valve function. Goldhaber et al20
reviewed the results from eight trials of systemic streptoki-
nase treatment for acute DVT and found that moderate or
significant lysis was achieved nearly three times more fre-
quently in patients treated with thrombolysis than in pa-
tients treated with anticoagulation alone. However, a four-
ombotic chronic venous disease was interpreted as “no
ysmography was normal. B, Results of a classic Linton
emoral vein, which neither phlebography nor hemody-
merota et al.7 Permission requested.st-thr
pleth
the ffold increased risk of major bleeding in those patients
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hemorrhagic morbidity of lytics rather than on their poten-
tial for long-term benefit.
The long-term efficacy of thrombus removal in patients
with acute iliofemoral DVT was further substantiated by
the Scandinavian investigators who performed a random-
ized trial of iliofemoral venous thrombectomy with an
arteriovenous fistula and anticoagulation vs anticoagulation
alone.21-23 Follow-up at 6 months, 5 years, and 10 years
demonstrated clear benefit in patients randomized to ve-
nous thrombectomy. Early thrombus removal resulted in
improved patency of the iliofemoral venous system, lower
venous pressures, less edema, and fewer post-thrombotic
symptoms.21,22 Although 10-year follow-up showed con-
sistent benefit of thrombectomy, the number of patients
surviving to 10 years was small, thereby reducing the sta-
tistical power of these observations.
The above observations, extending from the basic re-
search laboratory through systemic thrombolysis and oper-
ative venous thrombectomy, support the concept that
thrombus removal in patients with acute iliofemoral DVT
Table 1. Review of anticoagulation versus systemic lytic th
First author, year
Investigation
type/
patients (n)
Treatment
groups
Resolu
Significant
or complete
Browse,24 1968 PR/10 SK/5 3 (60)
Hep/5 0 (0)
Robertson,25 1968 PRB/16 SK/8 5 (63)
Hep/8 1 (12)
Kakkar,26 1969 PR/18 SK/9 6 (67)
Hep/9 2 (22)
Tsapogas,27 1973 PR/34 SK/19 10 (53)
Hep/15 0 (0)
Duckert,28 1975 PNRB/134 SK/92 39 (42)
Hep/42 0 (0)
Porter,29 1975§ PR/48 SK/22 9 (40)
Seaman,30 1976§ Hep/26 2 (8)
Rosch,31 1976§
Marder,32 1977 PR/24 SK/12 5 (42)
Hep/12 0 (0)
Arnesen,33 1978 PR/42 SK/21 11 (52)
Hep/21 2 (10)
Elliot,34 1979 PR/51 SK/26 17 (65)
Hep/25 0 (0)
Watz,35 1979 PR/35 SK/18 8 (44)
Hep/17 1 (6)
Jeffery,36 1989 PR/40 SK/20 11 (55)
Hep/20 1 (5)
Turpie,37 1990 PRB/82 rt-PA/40 13 (33)
Hep/42 2 (5)
Goldhaber,38 1990 PRB/67 rt-PA/45 15 (33)
Hep/12 0 (0)
PR, Prospective, randomized; PRB, prospective, randomized, blinded in
streptokinase; Hep, heparin; rt-PA, recombinant tissue plasminogen activat
*Intracranial hemorrhage.
†Nonfatal PE before therapy.
‡Fatal PE during therapy.
§Same study population.results in significantly less post-thrombotic morbidity. Un-fortunately, the favorable results of contemporary venous
thrombectomy have not generated much enthusiasm for
the operative procedure in the United States. In addition,
physicians are unwilling to accept the higher risk of bleed-
ing complications with lytic therapy; therefore, systemic
thrombolysis for acute DVT is infrequently used and not
recommended, which is appropriate in light of the im-
proved results with catheter-directed lysis.
TREATMENT STRATEGIES OF THROMBUS
REMOVAL
Systemic thrombolysis. Initial attempts to treat acute
DVT with thrombolytic therapy were by peripheral intra-
venous administration. Although treatment has evolved to
catheter-directed intrathrombus delivery, it is instructive to
review the information generated by trials of systemic
thrombolytic therapy vs anticoagulation for acute DVT.
Thirteen studies have been reported comparing antico-
agulant therapy with thrombolytic therapy for acute DVT
(Table I).24-38 The diagnosis in these studies was estab-
lished with ascending phlebography, which was repeated
y for deep vein thrombosis
esults, n (%) Complications, n (%)
tial
None or
propagation
Bleeding
PE
Death due
to RxMinor Major
20) 1 (20) 0 (0) 0 (0) None None
0) 5 (100) 0 (0) 0 (0) None None
25) 1 (12) 2 (25) 2 (25) NA None
25) 5 (63) 1 (12) 1 (12)* NA 1 (12)*
11) 2 (22) 0 (0) 3 (33) None None
22) 5 (56) 0 (0) 2 (22) None 1 (11)
0) 9 (47) 0 (0) 4 (21) NA None
7) 14 (93) NA NA NA None
25) 30 (33) 24 (26) 58 (62) 7 None
10) 38 (90) 4 (10) 2 (5) 5 None
5) 12 (55) 4 (17) 6 (25)* 1 1 (4)*
19) 19 (73) 1 (0.4) 7 (27) None None
16) 5 (42) NA NA NA 1 (8)*
25) 9 (75) NA NA NA None
19) 6 (29) 1 (5) 2 (10) 1† None
14) 16 (76) 1 (5) 2 (10) None None
4) 8 (31) 1 (4) 2 (8) None None
0) 25 (100) 0 (0) 0 (0) 2‡ None
22) 6 (34) 3 (12) 0 (0) 1 None
29) 11 (65) 2 (12) 0 (0) 1 None
0) 9 (45) NA NA NA None
0) 19 (95) NA NA NA None
22) 18 (45) 3 (8) 2 (5) NA None
17) 33 (78) 1 (2) 1 (2) NA None
31) 16 (36) 11 (24) 1 (2)* NA None
17) 10 (83) 0 (0) 0 (0) NA None
tation; PNRB, prospective, nonrandomized, blinded interpretation; SK,
, pulmonary embolism; NA, not available.erap
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or; PEafter treatment to assess outcome. Pooled analysis (Table II)
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tion alone had significant or complete lysis and an addi-
tional 14% had partial lysis. Most patients (82%) had either
no objective phlebographic clearing or actually had exten-
sion of their thrombi; therefore, few patients had sufficient
clearing of thrombus to expect return of normal venous
valvular function. In patients treated with thrombolysis,
45% had significant or complete clot resolution, 18% had
partial clearing, and 37% failed to improve or worsened.
Although 10 times as many patients had significant or
complete clearing with thrombolysis compared with anti-
coagulation, less than half of the lytic patients had a good-
to-excellent phlebographic outcome.
Two randomized trials monitored patients long term
and reported symptomatic results (Table III).34,39 Al-
though the Elliot et al follow-up period of 1.6 years was
shorter than the 6.5 years for Arnesen et al, both treatment
protocols were similar and used the same drug, streptoki-
nase. The investigators found that most patients who were
free of post-thrombotic symptoms were those treated with
streptokinase, whereas most patients with severe post-
thrombotic symptoms received anticoagulation alone.
A practical question is whether lysis of DVT preserves
venous valvular function. In a long-term follow-up of a
randomized study, Jeffery et al36 have shown significant
functional benefit to patients 5 to 10 years after successful
thrombolysis for acute DVT. Popliteal valve function and
overall venous insufficiency were assessed using photopl-
ethysmography, foot volumetry, and direct Doppler exam-
ination. Patients who had initially successful lysis demon-
strated normal venous function tests compared with
patients who did not lyse (P  .001). Only 9% of patients
who successfully lysed had an incompetent popliteal valve
Table II. Phlebographic results of anticoagulation versus
lytic therapy for acute deep venous thrombosis (13
studies)24-38
Rx (n)
Lysis
None/worse Partial
Significant
or complete
Heparin (254) 82% 14% 4%
Lytic Rx 37% 18% 45%
Table III. Long-term, symptomatic results of heparin
versus lytic therapy for deep venous thrombosis (two
studies)34,39
Rx
Post-thrombotic symptoms
Patients
(n)
Severe,
n (%)
Moderate,
(%)
None,
(%)
Heparin 39 8 (21) 23 (59) 8 (21)
Streptokinase 39 2 (5) 12 (31) 25 (64)compared with 77% of those who failed to lyse (P .001).Intrathrombus catheter-directed thrombolysis. It
is reasonable to expect that catheter-directed intrathrom-
bus delivery of thrombolytic agents will have improved lytic
outcomes compared with systemic delivery. The basic
mechanism of thrombolysis is the activation of fibrin-
bound plasminogen to form the active enzyme plasmin,
which dissolves clot.40 During thrombosis, circulating Glu-
plasminogen binds to fibrin and is converted to Lys-
plasminogen, which has more binding sites for plasmino-
gen activators and is more efficiently activated to plasmin
than Glu-plasminogen. Intrathrombus delivery naturally
protects plasminogen activators from neutralization by cir-
culating plasminogen activator inhibitor (PAI-1) and also
protects the resultant active enzyme plasmin from instanta-
neous neutralization by circulating antiplasmins. Catheter-
directed delivery of plasminogen activators into the throm-
bus accelerates thrombolysis, increasing the likelihood of a
successful outcome. Because accelerated lysis reduces the
overall dose and duration of plasminogen activator infu-
sion, it is reasonable to expect that complications also will
be reduced.
Numerous reports have demonstrated good outcomes of
catheter-directed thrombolysis for acute DVT (Table IV).41-59
Three large reports document a success rate of about
80%44-46 (Table V). Initial success rates likely would have
been higher in these series if treatment had been restricted
only to patients with acute iliofemoral DVT. However, as
clinicians gained technical expertise, patients with more
chronic and extensive thrombus were treated, resulting in
somewhat lower overall success rates. In these three studies,
422 patients were treated with consistent rates of both
success and complications. Notably, underlying iliac vein
stenoses were treated with balloon angioplasty, stenting, or
both, to achieve unobstructed venous drainage into the
vena cava, thereby reducing the risk of recurrent thrombosis.
Major bleeding complications occurred in 5% to 10% of
cases, with most located at the venous access site. Intracra-
nial bleeding was rare, occurring in only three patients in
the National Venous Registry.45 Symptomatic pulmonary
embolism occurred in 1% of patients in the series reported
by Bjarnason et al44 and the National Venous Registry,45
and fatal pulmonary embolism occurred in only one of the
422 patients; therefore, death as a result of catheter-
directed thrombolysis was rare.
Chang et al60 reported an interesting therapeutic ap-
proach using intrathrombus bolus dosing of recombinant
tissue plasminogen activator (rt-PA) in 12 lower extremities
of 10 patients with acute DVT. Using the pulse-spray
technique, they limited a single treatment session to 50 mg.
Patients were returned to their rooms and brought back the
next day for repeat phlebographic evaluation and repeat
infusion, if necessary, for a maximum of four sessions of
pulse-spray thrombolysis. Significant or complete lysis was
achieved in 11 of the 12 extremities, and one had 50% to
75% lysis. Although the average total dose of rt-PA was 106
mg, bleeding complications were minor and no patient had
a decrease in hematocrit of2%. This interesting technique
of intermittent pressure infusion of lytic agents deserves
tPA,
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population of DVT patients.
The National Venous Registry44 reported 287 patients
treated in both academic and community medical centers.
Of these, 66% had acute DVT, 16% had chronic DVT, 19%
had an acute episode superimposed upon a chronic condi-
tion, 71% presented with iliofemoral DVT, and 25% had
femoropopliteal DVT. Catheter-directed thrombolysis
with intrathrombus infusion of urokinase was the preferred
approach. In the subgroup of patients with acute, first-time
iliofemoral DVT, 65% of the patients enjoyed complete clot
Table IV. Review of studies of catheter-directed thrombo
First author, year
No of
patients
(limbs) Intervention/n
Semba,41 1994 21 (27) CDT with UK, angioplasty 
stenting for residual
stenosis
Semba,42 1996 32 (41) CDT with UK, angioplasty 
stenting for residual
stenosis
Verhaeghe,43 1997 24 CDT with rt-PA, stenting for
residual stenosis
Bjarnason,44 1997 77 (87) CDT with UK, angioplasty,
stenting, thrombectomy,
bypass for residual stenosis
Mewissen,45 1999 287 (312) CDT with UK, stenting for
residual stenosis; systemic
lysis/6
Comerota,46 2000 54 CDT with UK or rt-PA,
thrombectomy for residual
stenosis
Horne,47 2000 10 CDT with rt-PA
Kasirajan,48 2001 9 CDT with UK, rt-PA, or rPA
AbuRahma,49 2001 51 CDT w/ UK or rt-PA,
stents/18
Hep/33
Vedantham,50 2002 20 (28) CDT with UK, rt-PA, or rPA,
thrombectomy, stenting
Elsharawy,51 2002 35 CDT w/ SK, angio, stent/18
Hep/17
Castaneda,52 2002 15 CDT with rPA
Grunwald,53 2004 74 (82) CDT with UK, tPA, or rPA,
angioplasty, stenting
Laiho,54 2004 32 CDT with rt-PA/16
Systemic lysis with rt-PA/16
Sillesen,55 2005 45 CDT with rt-PA, angioplasty,
stenting
Jackson , 200556 28 CDT with UK or rPA,
stenting
Ogawa,57 2005 24 CDT with UK/10
CDT with UK  IPC/14
Kim,58 2006 37 (45) CDT with UK/23
CDT  PMT/14
Lin,59 2006 93 (98) CDT with rPA, rt-PA, or UK,
angioplasty, stenting/46
PMT with rPA, rt-PA, or UK,
angioplasty, stenting/52
CDT, Catheter-directed thrombolysis; Hep, heparin; IPC, intermittent pne
mechanical thrombolysis; rt-PA, recombinant tissue plasminogen activator;resolution.During follow-up, 65% of patients were thrombus-free
at 6 months and 60% at 12 months. There was a significant
correlation (P  .001) of thrombus-free survival with the
results of initial therapy. At 1 year, 78% of patients with
complete clot resolution initially had patent veins com-
pared with only 37% of those who had 50% lysis. An
important observation was made in the subgroup of pa-
tients with acute, first-time iliofemoral DVT who had ini-
tially successful thrombolysis: 96% of the veins in these
patients remained patent at 1 year. Initial lytic success also
directly correlated with valve function at 6 months: 62% of
for acute deep venous thrombosis
Resolution results, n (%) Complications, n (%)
ificant
mplete Partial None
Bleeding
PE
Death
due to
RxMinor Major
72) 5 (25) 2 (8) 1 (4) 0 (0) None None
32) 9 (28) 2 (6) 0 (0) 0 (0) None None
79) 5 (21) 0 (0)) 0 (0) 6 (25) None None
793) 0 (0) 18 (21) 11 (14) 5 (6) 1 None
31) 162 (52) 54 (17) 15 (28) 54 (11) 6 2 (1)
26) 28 (52) 6 (11) 8 (15) 4 (7) 1 None
90) 1 (10) 0 (0) 3 (30) None 2 (20) None
78) 1 (11) 1 (11) NA NA NA NA
83) NR NR 3 (17) 2 (11) None None
3) NR NR 3 (9) 2 (6) 2 (6) None
82) NR NR None 3 (14) None None
72) 5 (28) 0 (0) None None None None
12) 8 (47) 7 (41) None None None None
100) NR NR None None None None
73) 26 (32) NR 6 (8) 4 (5) None None
50) 5 (31) NR 4 (25) 2 (13) 2 (13) None
31) 8 (50) NR 6 (38) 1 (6) 5 (31) None
93) NR NR 4 (8) None 1 (2) None
18) 20 (72) NR 2 (7) None None None
0) 10 (100) None None None None None
36) 9 (64) None None None None None
81) 3 (11) 2 (8) 1 (4) 2 (7) 1 (4) None
84) 3 (16) None None 1 (5) 1 (5) None
70) 14 (30) 5 (11) 2 (4) 1 (2) None None
75) 13 (25) 4 (8) 2 (4) None None None
c compression; rPA, recombinant plasminogen activator; PMT, pharmaco-
tissue plasminogen activator; UK, urokinase.lysis
Sign
or co
18 (
21 (
19 (
69 (
96 (
14 (
9 (
7 (
15 (
1 (
23 (
13 (
2 (
15 (
54 (
8 (
5 (
42 (
5 (
0 (
5 (
21 (
16 (
32 (
39 (
umatipatients with 50% thrombolysis had venous valvular in-
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lysis had normal valve function (P  .02).
National Venous Registry patients with iliofemoral
DVT who were treated with catheter-directed thrombolysis
were compared with a contemporary cohort of patients
with iliofemoral DVT from the same institutions who were
treated with anticoagulation alone.61 All patients treated
only with anticoagulation were candidates for lytic therapy;
however, the choice of treatment was determined by phy-
sician preference. A validated quality-of-life (QOL) ques-
tionnaire62 was used to query patients at 16 and 22 months
after treatment. Of the 98 patients evaluated, 68 were
treated with catheter-directed thrombolysis and 30 with
anticoagulation alone. Those treated with catheter-
directed thrombolysis reported significantly better QOL
than those treated with anticoagulation alone.61 The QOL
results were directly related to the initial success of throm-
bolysis. Patients who had a successful lytic outcome re-
ported a significantly better health utilities index, increased
physical functioning, less stigma of chronic venous disease,
less health distress, and fewer overall post-thrombotic
symptoms. Patients in whom catheter-directed thrombol-
ysis failed had outcomes similar to those treated with anti-
coagulation alone. These efficacy data combined with the
reduced complications of intrathrombus infusion offer a
convincing argument for managing patients with iliofemo-
ral DVT with catheter-directed thrombolysis.
Meissner and Mewissen63 recently reported follow-up
results in 102 limbs of 98 patients with acute first-time
DVT treated in the National Venous Registry. The median
Table V. Efficacy and complications of catheter-directed
thrombolysis in three series
Results
First author of study
Bjarnason44
(n  77)
Mewissen45
(n  287)
Comerota,46
(n  58)
Efficacy
Initial success 79% 83% 84%
Iliac 63% 64% 78%
Femoral 40% 47% —
Primary patency
at 1 yr
Iliac 63% 64% 78%
Femoral 40% 47% —
Iliac stent: patency
at 1 yr
 stent 54% 74% 89%
 stent 75% 53% 71%
Complications
Major bleed 5% 11% 9%
Intracranial bleeding 0% 1% 0%
Pulmonary embolism 1% 1% 0%
Fatal pulmonary
embolism
0% 0.20% 0%
Death secondary to
lysis
0% 0.40% 0% (?2%)*
*Death due to multiorgan system failure 30 days post lysis, thought not
related to lytic therapy.follow-up time was 316 days. The authors correlated thelytic response with residual thrombus, vein valve function,
and post-thrombotic symptoms (Table VI). A good or
excellent lytic response was associated with significantly less
thrombus, less vein valve reflux, and a greater number of
asymptomatic patients.
A small randomized trial performed by Elshawary et al51
compared catheter-directed thrombolysis with anticoagu-
lation alone. These authors demonstrated that catheter-
directed thrombolysis offered considerably better out-
comes at 6 months. Assuming that the post-thrombolysis
management of patients with anticoagulation is effective
and of proper duration, this 6-month observation should
reflect long-term outcome.
Contemporary venous thrombectomy. Advances in
all methods to eliminate thrombus from the deep venous
system have occurred during the past 10 to 15 years.
Contemporary venous thrombectomy has substantially
improved the early and long-term results of patients with
extensive iliofemoral DVT compared with the initial
reports.21-23,64-70 Major technical advances occurring
between the initial and contemporary procedures are
listed in Table VII. The technical details of contem-
porary venous thrombectomy have been previously
reported.71,72
In an important randomized trial, Plate et al22 compared
operative venous thrombectomy with arteriovenous fistula
Table VI. Results of catheter-directed thrombolysis for
acute deep venous thrombosis: follow-up to the National
Venous Registry63
Lytic response to catheter-directed
thrombolysis
Outcome at follow-up
(316 days median)
50%
(n  11)
50%-99%
(n  53)
100%
(n  38) P
Residual thrombus 73% 45% 16% .001
Reflux 89% 48% 39% .03
Asymptomatic 36% 68% 84% .002
Table VII. Venous thrombectomy: comparison of old
and contemporary techniques
Technique Old Contemporary
Pretreatment phlebography/
CT scan Occasionally Always
Venous thrombectomy catheter No Yes
Operative fluoroscopy/
phlebography No Yes
Correct iliac vein stenosis No Yes
Arteriovenous fistula No Yes
Infrainguinal thrombectomy No Yes
Intraoperative thrombolysis No Yes
Full post op anticoagulation Occasionally Yes
Catheter-directed anticoagulation No Yes
IPC post-op No Yes
CT, Computed tomography; IPC, intermittent pneumatic compression.(AVF) plus anticoagulation vs anticoagulation alone in pa-
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at 6 months,22 5 years,21 and 10 years23 of follow-up. Patients
randomized to venous thrombectomy had improved pa-
tency (P  .05), reduced venous pressures (P  .05), less
edema (P  .05), and fewer post-thrombotic symptoms
(P  .05) than those receiving only anticoagulation. Of
interest was that more patients undergoing venous throm-
bectomy had preserved normal venous valve function in
their femoropopliteal segment than patients who were
treated with anticoagulation alone.21,22 Recall that previ-
ously discussed studies of the natural history of acute DVT
treated with anticoagulation reported valve incompetence
in veins distal to proximal obstruction, even when the
distal veins were not involved with clot. Hence, elimina-
tion of iliofemoral thrombus (and proximal venous ob-
struction) potentially protected the distal valves from the
hemodynamic consequences of obstructed proximal
veins and resultant valvular incompetence of the distal
veins.14
Blattler et al73 combined venous thrombectomy of the
iliofemoral venous system with urokinase infusion into the
leg with a thigh tourniquet to aid removal of the infrain-
guinal venous thrombi. This resulted in patent veins in all
33 patients treated in this manner, with no recurrence or
post-thrombotic symptoms at 1 year. By 10 years of follow-
up, three patients had recurrent DVT (not in the treated
leg) and two had venous claudication.
Unfortunately, the American College of Chest Physi-
cians (ACCP) Consensus Guidelines74 failed to recognize
recently published data when they recommended against
operative venous thrombectomy, focusing attention in-
stead on reports of patients treated 40 years ago. Al-
though randomized trial data demonstrated significant
benefit of venous thrombectomy, influential guidelines
such as the ACCP’s reduced or eliminated enthusiasm for
operative thrombectomy.
Pharmacomechanical thrombolysis. Complementing
catheter-directed thrombolysis with adjunctive mechanical
methods is rapidly becoming the standard for catheter-
based management of extensive venous thrombosis.75-77
Percutaneous mechanical thrombectomy alone is less suc-
cessful than catheter-directed thrombolysis and is associ-
ated with unacceptably high complications of pulmonary
emboli (PE). Pulse-spray pharmacomechanical thromboly-
sis of clotted hemodialysis grafts demonstrated an 18%
incidence of PE in patients treated with a plasminogen
activator solution compared with a 64% incidence of PE in
patients treated with a heparinized saline solution (P 
.04).78 Because the hemodialysis graft is in direct commu-
nication with the venous circulation, it appears that results
in these patients should be similar to patients with proximal
acute DVT. The caliber of the proximal deep veins is
substantially larger than a 6-mm dialysis access graft; thus,
one would expect that these observations would be magni-
fied when treating proximal DVT.
In an experimental model comparing mechanical, phar-
macomechanical, and pharmacologic thrombolysis, Green-
berg et al79 reported findings consistent with Kinney et al78by demonstrating that pulse-spray mechanical thrombec-
tomy was associated with the largest number and greatest
size of distal emboli. Embolic particles diminished in num-
ber and size and the speed of lysis increased when
urokinase was added to the pulse-spray solution. Catheter-
directed thrombolysis alone was associated with the slowest
rate of reperfusion but also the fewest number of distal
emboli.
Hemolytic complications of rheolytic mechanical throm-
bectomy are common and occasionally result in anemia and
renal dysfunction. Recent favorable observations using a mod-
ifiedpercutaneousthrombectomydevice inatable-topmodel80
require confirmation in a biologic model and ultimately in
patients.
A new device recently released for isolated segmental
and controlled pharmacomechanical thrombolysis is the
re-engineered Trellis catheter (Bachus Vascular, Santa
Clara, Calif). This hybrid catheter isolates the thrombosed
vein segment between two occluding balloons and a lytic
agent is infused into the thrombus. The intervening cathe-
ter shaft assumes a spiral configuration, which is then motor
activated and spins at 1500 rpm. After 15 to 20 minutes,
the liquefied thrombus and remaining fragments are aspi-
rated. Phlebographic evaluation of the result is performed
before moving on to treat additional thrombosed vein
segments. The advantages of such a device include its ability
to incorporate mechanical and pharmacologic therapies
and to treat patients who have traditional contraindications
to thrombolytic therapy. Because the infusate is aspirated
and the clot more rapidly lysed, treatment times are signif-
icantly shortened.
Another interesting new adjunct to catheter-directed
thrombolysis is the incorporation of ultrasound transducers
into the infusion catheter. Ultrasound waves generated
during t-PA infusion increases the surface area of fibrin and
speeds lysis. Several reports have emerged indicating that an
infusion catheter with ultrasound transducers built into the
infusion end of the catheter can be used to accelerate
thrombolysis.81-84 In vitro studies have demonstrated that
ultrasound enhances the fibrinolytic activity of t-PA.85-87
The potential mechanism for augmented clot lysis has been
extrapolated from in vitro studies showing that ultrasound
produces clot fragmentation in the presence of t-PA, and
consequently, more fibrin-binding sites are available to
t-PA owing to the larger surface area.88,89 The concept of a
transducer-tip catheter that delivers a fibrinolytic drug in
combination with high-frequency, low-intensity ultra-
sound has been well described. In vivo models90 and clin-
ical trials91 are now underway to assess the potential value
of ultrasound enhancement of thrombolytics for the man-
agement of acute DVT.
A patient with extensive iliofemoral, popliteal, and tib-
ial DVT was treated with pharmacomechanical thrombol-
ysis using isolated segmental pharmacomechanical lysis
with the Trellis catheter and ultrasound-accelerated throm-
bolysis with the Lysus catheter (EKOS Corporation, Bothell,
Wash; Figs 2, 3, and 4). Properly applied, these techniques
e ank
JOURNAL OF VASCULAR SURGERY
November 20071072 Comerota and Gravettcan significantly speed thrombus resolution, restore pa-
tency, and preserve valve function.
Current catheter-based thrombolytic techniques are
Fig 2. Extensive deep vein thrombosis is demonstrat
laparotomy. Clot was found extending from his calf veins
et al.7 Permission requested.
Fig 3. A, Trellis catheter (Bachus Vascular, Santa Clara
through the popliteal vein. B, Lysus catheter (EKOS Cor
segment, accessed through the posterior tibial vein at thmore effective and are safer. As technology continues toimprove, lytic infusion times will shorten, more patients
will be offered a treatment strategy that includes throm-
bus removal, and many more patients will be spared their
lebographically in a patient 2 days after exploratory
e proximal common iliac vein. Adapted from Comerota
if) (arrows) in the iliofemoral venous segment, accessed
ion, Bothell, Wash; arrow) in the tibial-popliteal venous
le. Adapted from Comerota et al.72 With permission.ed ph
to th, Cal
poratotherwise certain post-thrombotic morbidity.
t al.7
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PATIENTS WITH ILIOFEMORAL DEEP
VENOUS THROMBOSIS
The general treatment strategy for patients with
Fig 4. Completion phlebogram after pharmacomechan
the calf veins to the vena cava. At 16 months’ follow-up, t
system, and normally functional venous valves. Adapted
Fig 5. Algorithm illustrates our current treatment pro
(DVT). CT, Computed tomography; CD, catheter d
Vascular, Santa Clara, Calif. Reprinted from Comerota eacute iliofemoral DVT is summarized in the algorithmillustrated in Fig 5. All patients undergo immediate
anticoagulation, are placed in snug, long-leg, multilay-
ered compression bandages extending from the base of
the toes to the upper thigh, and treated with leg
hrombolysis demonstrates a patent venous system from
tient had no post-thrombotic symptoms, a patent venous
Comerota et al.72 With permission.
for patients with iliofemoral deep venous thrombosis
d; PM, pharmacomechanical. Trellis catheter, Bachus
Permission requested.ical t
he pa
from
tocol
irecteelevation.92 Patients are permitted to ambulate. When
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elevated.
A rapid computed tomography (CT) scan with contrast
is performed of the chest, abdomen, and pelvis to evaluate
for PE and other pathology that may be associated with
their aggressive degree of thrombosis. Patients who are
physically active are considered for a strategy of thrombus
removal. Anticoagulation with compression is generally
recommended for patients who are minimally active or have
a lifespan of 2 years. A vena cava filter should be inserted
in patients who have a free-floating thrombus in their vena
cava.
Patients considered for a strategy of thrombus removal
who have a contraindication to thrombolysis are treated either
with a contemporary venous thrombectomy71 or segmental
pharmacomechanical thrombolysis using the Trellis catheter.
Patients with no contraindication to thrombolysis are offered
catheter-directed thrombolysis with additional pharmacome-
chanical techniques.
Once the thrombus is removed, a completion phlebo-
gram is performed to assess for an underlying venous lesion,
which should be corrected to provide unobstructed venous
drainage into the vena cava, thereby reducing the risk of
recurrent thrombosis. Subsequently, therapeutic anticoag-
ulation is important to avoid recurrent thrombosis. Inter-
mittent pneumatic compression units are applied while
patients remain hospitalized and not ambulating. If an
underlying etiology for the patient’s extensive venous
thrombosis cannot be identified, a thrombophilia evalua-
tion is performed.
CONCLUSION
Post-thrombotic morbidity after iliofemoral DVT is
certain.1-3 The more extensive the thrombosis and the more
active the patient, the more severe the post-thrombotic
sequelae. Active patients with an anticipated survival of2
years should be offered a strategy of thrombus removal to
avoid chronic venous obstruction and multisegment valvu-
lar incompetence.
Long-term benefits of a strategy of restoring venous
patency have been documented in a randomized trial of
venous thrombectomy vs anticoagulation,20-22 and short-
term benefits have been shown in a trial of catheter-directed
thrombolysis vs anticoagulation.55 Patients receiving ve-
nous thrombectomy had significantly better venous pa-
tency rates, lower venous pressures, better valve function,
and less post-thrombotic morbidity. Patients randomized
to catheter-directed thrombolysis had significantly better
patency and valve function compared with patients ran-
domized to anticoagulation. Likewise, randomized trials of
systemic thrombolytic therapy show that when it is success-
ful, patients have fewer post-thrombotic sequelae and im-
proved venous function compared with patients treated
with anticoagulation alone or when lytic therapy is unsuc-
cessful.18
Improvements in operative technique as well as catheter-
based technology now document higher rates of success and
lower complication rates. As clinicians become more experi-enced with these techniques, technology continues to im-
prove, and new pharmacologic agents are developed that lyse
thrombus more rapidly with fewer bleeding complications,
the application of these principles should expand.
The medical community awaits a large-scale random-
ized trial comparing an endovascular strategy of thrombus
removal with anticoagulation for patients with acute DVT.
Trial design is critical, however. If only patients with exten-
sive DVT are studied, there is little question in our opinion
that a strategy of thrombus removal will prove superior.
However, inclusion of lesser degrees of thrombosis will
reduce the relative benefit of treatment strategies designed
to eliminate thrombus, because endogenous fibrinolysis
will accomplish this in some treated with anticoagulation
alone. Single venous segment involvement, such as the
femoral vein in the thigh, often does not cause significant
post-thrombotic morbidity. The femoral vein can be sacri-
ficed (ligated) with minimal morbidity in most patients
because collateral drainage exists through the profunda
femoris venous system. Therefore, selecting patients most
likely to benefit from a strategy of thrombus removal, such
as those with multilevel venous thrombosis, is crucial to
clarifying efficacy.
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